Interagency Patent Coordination and Improvement Act of 2023

The Interagency Patent Coordination and Improvement Act of 2023 creates a formal task force to improve information sharing between the U.S. Patent and Trademark Office (USPTO) and the Food and Drug Administration (FDA) regarding patents for human drugs and biological products. It requires the agencies to establish protocols for sharing relevant drug approval details, scientific developments, and patent-related information to help USPTO examiners assess prior art and technology. The bill includes strict confidentiality safeguards, such as notifying drug sponsors before sharing information and maintaining secure handling of sensitive data. The USPTO must report to Congress within four years on the task force's effectiveness and recommend potential improvements to the coordination process.